SGLT2 inhibitor

Developed for: COVID-19
Investigated by: Matthew Neal MD · National Heart, Lung, and Blood Institute (NHLBI)

today NCT04505774 · Ph 4

202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 4	NCT04505774	Sep 2020 → Aug 2023	COVID-19	Matthew Neal MD	Completed	Missed primary

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	SGLT2 inhibitor	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04505774 ↗
Route	Oral	“administered orally, once daily” PMID 39250922 ↗ Sep 2024